Amylyx Pharmaceuticals Inc. said Wednesday that Nasdaq has halted trading of its common stock before a meeting with the U.S. Food and Drug Administration.
The stock last traded up 5% to $15.68 in premarket trading.
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee is meeting Wednesday to review the New Drug Application for AMX0035 sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
The advisory committee meeting is scheduled for 10 a.m. ET.
The Prescription Drug User Fee Act target action date for the AMX0035 NDA is June 29, 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.